Drug Discovery@nature.com 7 December 2012

TABLE OF CONTENTS 7 December 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Reviews Immunology POSTER-THE IMMUNE RESPONSE TO HIV Authors: Nina Bhardwaj, Florian Hladik and Susan Moir www.nature.com/nri/posters/hiv Produced with support from STEMCELL Technologies   News Top Companies in footrace to deliver RNAi doi:10.1038/nbt1212-1154 The past year has seen a resurgence of interest in RNAi therapies and a number of improvements to RNAi delivery and stability. Full Text First gene therapy approved doi:10.1038/nbt1212-1153 It is hoped that the recent approval of Glybera in Europe will open up the market for other gene therapies. Full Text Belgian biotech's clot-buster approved for aging eyes doi:10.1038/nbt1212-1158b ThromboGenics's recombinant protein drug Jetrea, which received US regulatory approval in October, is predicted to be a commercial success. Full Text An Audience With: Chris Lipinski doi:10.1038/nrd3895 Chris Lipinski, originator of the 'rule of five' guidelines for predicting the oral bioavailability of drug candidates, discusses their impact as well as efforts to expand drug-like chemical space and drug repositioning initiatives. Full Text Analysis Top Multitasking E selectin doi:10.1038/scibx.2012.1197 Researchers have mouse data showing that E selectin antagonists can alleviate side effects of chemotherapy brought about by exhaustion of the self-renewal capacity of hematopoietic stem cells. Full Text Factors influencing non-approval of new drugs in Europe doi:10.1038/nrd3894 This analysis looked at marketing applications at the EMA for new active substances, revealing the extent to which certain underlying factors were associated with failure to be approved. Full Text Research Highlights Top Drug screening: A MuSIC-al way to identify drug pairs doi:10.1038/nrd3898 Researchers have a new method to identify synergistic drug pairs and new targets for the potential treatment of HIV. The method could be applicable to other therapeutic areas where combinations of drugs might offer improved benefits. Full Text Analgesics: Deadly snake venom for pain relief? doi:10.1038/nrd3897 Proteins from snake venom function as potent painkillers with a novel mechanism of action. They could be useful tools for dissecting pain pathways, as well as having potential therapeutic value themselves. Full Text Neurodegenerative diseases: Novel route to neuroprotection doi:10.1038/nrd3899 Compounds from a series based on P7C3 — an aminopropyl carbazole with neurogenic properties — have therapeutic effects in animal models of Parkinson's disease and amyotrophic lateral sclerosis. Full Text Research & Reviews Top Protein kinase C, an elusive therapeutic target? doi:10.1038/nrd3871 This Review looks at the efforts, challenges and opportunities for the protein kinase C family, which have been a major focus of drug discovery efforts. Full Text Tankyrase-targeted therapeutics: expanding opportunities in the PARP family doi:10.1038/nrd3868 This Review focuses on the biology of tankyrases and the discovery of tankyrase-specific inhibitors. It also considers the challenges that lie ahead for the clinical development of PARP family inhibitors in general. Full Text Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease–like pathology and cognitive decline doi:10.1038/nm.2965 New research shows that inhibition of IL-12 and IL-23 signaling reduces plaque load and improves cognitive deficits in mouse models of Alzheimer's disease. The researchers suggest that this pathway may be targeted therapeutically. Full Text Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis doi:10.1038/nbt.2434 Researchers have shown that microparticles bearing encephalitogenic peptides induce long-term T-cell tolerance in mice with relapsing experimental autoimmune encephalomyelitis, preventing the onset and modifying the course of the disease. Full Text Drug Discovery JOBS of the week Drug Discovery for Helminths Aroian Group, University of California, San Diego Assistant / Associate Professor-Chemical Biology / Medicinal Chemistry / Drug Discovery Wayne State University Associate Professor in Drug Discovery (fixed-term) The University of Nottingham Key Postdoctoral Position at Wits Advanced Drug Delivery Platform Available Immediately University of the Witwatersrand, Johannesburg, South Africa PhD Position: Functionalized Inorganic Materials for Water Remediation and Drug Delivery University of Southern Denmark, Department of Physics, Chemistry and Pharmacy More Science jobs from Drug Discovery EVENT 5th international conference on drug discovery and therapy 18.-21.02.13 Dubai, UAE More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.